Anzeige
Mehr »
Dienstag, 03.03.2026 - Börsentäglich über 12.000 News
Erste Psilocybin-Behandlungen laufen - warum steht Optimi noch bei Pennystock-Level?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker-Symbol: 2I9
Frankfurt
02.03.26 | 08:37
0,000 Euro
-85,71 % -0,001
1-Jahres-Chart
KDVENTURES AB Chart 1 Jahr
5-Tage-Chart
KDVENTURES AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,0120,03802.03.

Aktuelle News zur KDVENTURES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrChange of number of shares and votes in KDventures AB1
KDVENTURES Aktie jetzt für 0€ handeln
24.02.KDventures AB: KDventures's portfolio company SVF Vaccines announces that the intended merger with Novakand will not be carried out following negative decision from Nasdaq172STOCKHOLM, Sweden, February 24, 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed...
► Artikel lesen
13.02.KDventures AB: Year-end Report - January-December 2025131STOCKHOLM - 13 February 2025. KDventures AB (Nasdaq Stockholm: KDV) today publishes its Year-end Report January-December 2025. The full report is available on the Company's website. "A stronger financial...
► Artikel lesen
12.02.KDventures AB (publ): KDventures AB (publ) carries out a directed issue of shares to guarantors in connection with the completed rights issue173NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
► Artikel lesen
10.02.KDventures AB (publ): KDventures' portfolio company SVF Vaccines appoints Raheleh Nassaji as Chief Executive Officer246STOCKHOLM, Sweden, 10 February 2026. KDventures AB (Nasdaq Stockholm: KDV) announces that its portfolio company SVF Vaccines has appointed Raheleh Nassaji as Chief Executive Officer to lead the transition...
► Artikel lesen
09.02.Change of issuer name and symbol for Karolinska Development AB185As from February 10, 2026, Karolinska Development AB will change issuer name and symbol. Old issuer name: Karolinska Development AB New issuer name: KDventures AB Old symbol: KDEV New symbol: KDV ISIN...
► Artikel lesen
06.02.Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement147STOCKHOLM, Sweden, February 6, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has entered into a reverse acquisition agreement with Novakand...
► Artikel lesen
28.01.Karolinska Development AB: Karolinska Development AB (publ) announces the outcome of the rights issue and change of the company name to KDventures AB280NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
► Artikel lesen
23.01.Karolinska Development AB (publ): Karolinska Development AB receives additional guarantee commitments in ongoing rights issue346NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
► Artikel lesen
21.01.Karolinska Development AB (publ): Karolinska Development's portfolio company Dilafor signs binding term sheet with Exeltis for a license agreement regarding tafoxiparin167STOCKHOLM, SWEDEN - January 21, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Dilafor has signed a binding term sheet with Exeltis, a global Women's...
► Artikel lesen
13.01.The subscription period in Karolinska Development AB (publ)'s rights issue begins today1
12.01.Listing of subscription rights and paid subscription shares of Karolinska Development AB217With effect from January 13, 2026, the subscription rights of Karolinska Development AB will be traded on the list for Equity rights. Trading will continue up until and including January 22, 2026. ...
► Artikel lesen
09.01.Karolinska Development AB (publ) announces publication of information document in connection with upcoming rights issue163NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH...
► Artikel lesen
08.01.Karolinska Development AB (publ): Karolinska Development's Extraordinary General Meeting 2026294STOCKHOLM, SWEDEN - January 8, 2026. Karolinska Development AB (publ) ("Karolinska Development" or the "Company") held an Extraordinary General Meeting on January 8, 2026, at which the shareholders...
► Artikel lesen
07.01.XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026599Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON...
► Artikel lesen
22.12.25Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development189STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand...
► Artikel lesen
11.12.25Karolinska Development AB (publ): Karolinska Development's portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D192STOCKHOLM, Sweden, December 11, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented new preclinical data on its immunotherapy SVF-001...
► Artikel lesen
10.12.25Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia195STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a...
► Artikel lesen
10.12.25Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01151STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has reported strong, positive results from the phase 2a...
► Artikel lesen
02.12.25Notice of Extraordinary General Meeting in Karolinska Development AB (publ)126The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, ("Karolinska Development" or the "Company") are invited to the Extraordinary General Meeting ("EGM"), on Thursday January...
► Artikel lesen
Weiter >>
45 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1